Skip to content

Samuel J Carter

Institute for Psychedelics and Neurotherapeutics, University of California, Davis, CA 95616.

3 papers in the library · 56 citations · publishing 2025

Papers

Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential

Proceedings of the National Academy of Sciences April 14, 2025 Jeremy R Tuck, Lee E Dunlap, Yara A Khatib et al. 32 citations

A newly designed compound, (+)-JRT, structurally similar to LSD but with reduced hallucinogenic effects, promotes the growth of dendritic spines in the cortex—a process that is diminished in neuropsychiatric diseases such as depression, addiction, and schizophrenia. In behavioral tests, (+)-JRT showed antidepressant-like and cognition-enhancing effects without worsening signs related to psychosis. This suggests that nonhallucinogenic compounds that promote neuroplasticity could be safer alternatives to psychedelics for treating conditions where psychedelics pose risks.

Efficient and modular synthesis of ibogaine and related alkaloids.

Nature chemistry March 1, 2025 Rishab N Iyer, David Favela, Andras Domokos et al. 22 citations

A new chemical method produces ibogaine in seven steps from pyridine, enabling gram-scale synthesis. This approach also creates three additional iboga alkaloids, the unnatural enantiomer (+)-ibogaine, and four analogues. Biological tests show that (+)-ibogaine does not affect cortical neuron growth like natural ibogaine, while (-)-10-fluoroibogamine strongly promotes neuron growth and potently modulates the serotonin transporter. The work provides a platform for making iboga alkaloids and related compounds for further study, supporting research into their therapeutic potential for addiction and other neuropsychiatric conditions.

Design, Synthesis, and In Vitro Characterization of a Tryptamine-Based Visible-Light Photoswitchable 5-HT2AR Ligand Showing Efficacy Preference for β-Arrestin over Mini-Gq.

Journal of medicinal chemistry June 18, 2025 Alexandra Sink, Eline Pottie, Samuel J Carter et al. 2 citations

A photoswitchable ligand for the serotonin 2A receptor (5-HT2AR) was designed to independently study G protein- and β-arrestin2-dependent signaling pathways. The cis-photoisomer binds the receptor with greater affinity than the trans-isomer, at nanomolar concentrations. In functional assays, this ligand showed a preference for recruiting β-arrestin2 over mini-Gαq relative to LSD, offering a tool to investigate β-arrestin2's role in 5-HT2AR signaling and its potential involvement in psychedelic effects.